Venkata Chinnakotla, MD
Endocrinology, Diabetes & Metabolism · Columbia, SCNPI 1033559604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,189, more than ten times the $210 reported in 2019.
Across 152 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$372
- Insulet Corporation$370
- Medtronic$358
- Amgen$248
- Lilly USA, LLC$218
- Xeris Pharmaceuticals, Inc.$217
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,66998%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 9 | $372 |
| Insulet Corporation | 12 | $370 |
| Medtronic(2 entities) | 14 | $358 |
| Amgen(2 entities) | 11 | $248 |
| Lilly USA, LLC | 11 | $218 |
| Xeris Pharmaceuticals, Inc. | 11 | $217 |
| Sequel Med Tech, LLC | 5 | $164 |
| Cequr Corporation | 4 | $157 |
| Radius Health, Inc. | 5 | $142 |
| Novo Nordisk | 6 | $141 |
| AstraZeneca(2 entities) | 6 | $129 |
| AbbVie | 8 | $126 |
| Ascensia Diabetes Care US Inc. | 5 | $109 |
| Corcept Therapeutics | 5 | $107 |
| Sanofi-aventis U.S. LLC | 3 | $100 |
| Tandem Diabetes Care, Inc. | 4 | $89 |
| Dexcom, Inc. | 4 | $84 |
| Recordati_rare_diseases_inc. | 3 | $71 |
| Abbott | 3 | $63 |
| Ascendis Pharma Endocrinology Inc | 3 | $61 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Antares Pharma, Inc. | 3 | $50 |
| Chiesi USA, Inc. | 2 | $44 |
| Boehringer Ingelheim | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Almatica Pharma LLC | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Bayer | 1 | $21 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,733 in reported general payments places this provider in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $256,791 |
| MounjaroTirzepatide | 88 | $150,022 |
| TrulicityDulaglutide | 40 | $70,755 |
| JardianceEmpagliflozin | 68 | $69,127 |
| FarxigaDapagliflozin Propanediol | 33 | $45,102 |
| JanuviaSitagliptin Phosphate | 38 | $40,592 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $38,156 |
| TradjentaLinagliptin | 39 | $34,015 |
| RybelsusSemaglutide | 17 | $31,739 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $31,495 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $27,940 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $26,736 |
| Gvoke Hypopen 2-PackGlucagon | 34 | $21,100 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $17,888 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $16,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $141 | $288,529221 claims |
| Lilly USA, LLCMounjaro, Trulicity | $218 | $220,777128 claims |
| Boehringer IngelheimJardiance, Tradjenta | $44 | $103,142107 claims |
| AstraZenecaFarxiga | $129 | $45,10233 claims |
| AbbVieSynthroid | $126 | $4,23336 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $2,508214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Columbia
- Basem MishrikyColumbia$14K
- Brooke McAdamsColumbia$5K
- Ali RizviColumbia$4K
- Yenny Otalora RojasColumbia$3K
- Pushyami MikkilineniColumbia$2K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.